经导管主动脉瓣置换术治疗单纯主动脉瓣反流的研究进展  

Advances in transcatheter aortic valve replacement for pure native aortic regurgitation

作　　者：刘路路[1] 石峻[1] 钱宏[1] 郭应强[1] LIU Lulu;SHI Jun;QIAN Hong;GUO Yingqiang(Department of Cardiovascular Surgery,West China Hospital,Sichuan University,Chengdu,610041,P.R.China)

机构地区：[1]四川大学华西医院心脏大血管外科

出　　处：《中国胸心血管外科临床杂志》2019年第12期1266-1270,共5页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

摘　　要：经导管主动脉瓣置换术(transcatheter aortic valve replacement,TAVR)治疗高龄高危主动脉瓣狭窄具有较好的安全性和有效性,其治疗中、低危主动脉瓣狭窄临床效果不劣于外科手术。手术技术和器械的发展使心脏外科医生尝试拓宽其适应证,许多高龄高危单纯主动脉瓣反流患者也得到了TAVR治疗,从而完成人工瓣膜置换,恢复瓣膜功能,改善预后。但也因手术技术要求高、手术并发症多等因素,目前缺乏随机对照研究证实其安全有效性。单纯主动脉瓣反流的瓣膜复合体结构改变与退行性主动脉瓣狭窄不同,经导管瓣膜需要克服独特的挑战。本文将对TAVR治疗主动脉瓣反流的研究进展作一综述。Transcatheter aortic valve replacement(TAVR)has been confirmed to be safety and efficacy for highrisk elderly aortic stenosis,and the clinical effect of TAVR for medium and low-risk aortic stenosis is not worse than that of surgery.The development of surgical techniques and instruments has made cardiologists attempt to broaden the surgical indications.Many elderly and high-risk patients with pure native aortic regurgitation have been treated"off label"with similar techniques,completing artificial valve replacement,restoring valve function and improving the prognosis.However,due to the high requirements of surgical techniques and surgical complications,there is a lack of randomized controlled studies to confirm its safety and effectiveness.Unlike aortic stenosis,native aortic regurgitation presents unique challenges for transcatheter valves.In this article,the authors review current advances in the treatment of aortic valve regurgitation with TAVR.

关 键 词：主动脉瓣反流 瓣膜 经导管主动脉瓣置换 

分 类 号：R65[医药卫生—外科学]